Skip to main content

Ischaemic Heart Disease

2
Pipeline Programs
3
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

CirCode Biomed
CirCode BiomedChina - Shanghai
1 program
1
HM2002 injectionPhase 11 trial
Active Trials
NCT06621576Active Not Recruiting3Est. Sep 2025
Biomed
BiomedAustralia - Sydney
1 program
1
HM2002 injectionPhase 1
Abbott
AbbottABBOTT PARK, IL
1 program
Angiographic guided PCIN/A1 trial
Active Trials
NCT03171311Active Not Recruiting1,201Est. May 2029

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
CirCode BiomedHM2002 injection
AbbottAngiographic guided PCI

Clinical Trials (2)

Total enrollment: 1,204 patients across 2 trials

First-in-Human Pilot Study of Epicardial Circular RNA-HM2002 Injection in CABG for Ischemic Heart Failure

Start: Sep 2024Est. completion: Sep 20253 patients
Phase 1Active Not Recruiting
NCT03171311AbbottAngiographic guided PCI

The OCTOBER Trial - European Trial on Optical Coherence Tomography Optimized Bifurcation Event Reduction (OCTOBER)

Start: Jul 2017Est. completion: May 20291,201 patients
N/AActive Not Recruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.